Key Points – BioHarvest Sciences reported first-quarter revenue of $8.5 million, up 8% year over year, and kept its 2026 guidance unchanged for both the D2C and CDMO businesses.
Cash and deposits rose sharply to $20.2 million from $3.4 million a year earlier. – The company is reorganizing around a two-business structure: the VINIA direct-to-consumer segment and the CDMO platform
Management said this should improve capital allocation and execution, while also preparing for a new manufacturing facility expected to begin production in 2H 2027. – BioHarvest highlighted CDMO progress in fragrance and saffron, including a $1.2 million stage 2 fragrance contract and completion of saffron stage 1. Management also said it expects more CDMO projects ahead and remains focused on a marketing reset for VINIA to improve customer acquisition efficiency. BioHarvest Sciences (NASDAQ:BHST) reported higher first-quarter revenue and reiterated its 2026 outlook as management detailed a broader reorganization around two business lines: its direct-to-consumer VINIA products business and its contract development and manufacturing organization, or CDMO, platform.
The plant cell culture biotechnology company said revenue for the first quarter of 2026 rose 8% year over year to $8.5 million, compared with $7.9 million in the prior-year period. Gross profit increased to $5 million, or 59% of revenue, from $4.6 million, or 58% of revenue, a year earlier. Net loss widened to $2.6 million, or $0.11 per basic and diluted share, compared with a net loss of $2.3 million, or $0.13 per basic and diluted share, in the same quarter last year.